ZHONGSHENGYAOYE(SZ:002317)2026-01-26 12:05Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between ¥26,000.00 million and ¥31,000.00 million, representing a growth of 186.91% to 203.62% compared to the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between ¥27,000.00 million and ¥32,000.00 million, indicating a growth of 203.72% to 222.93% year-over-year[3]. - The basic earnings per share is expected to be between ¥0.31 and ¥0.37, a significant recovery from a loss of ¥0.36 per share in the previous year[3]. - The anticipated growth in net profit is primarily due to the impact of asset impairment losses and non-recurring gains and losses in 2024, which totaled ¥54,668.07 million and reduced the net profit by ¥48,409.79 million[6]. - The company reported non-recurring losses of ¥3,884.44 million in 2024, primarily due to fair value changes in trading financial assets and litigation-related provisions[6]. Strategic Focus - The company has successfully launched two innovative drugs, which are expected to be key growth drivers for future performance[5]. - The company emphasizes a strategic focus on innovation in the treatment of metabolic and respiratory diseases, aiming to enhance overall performance[5]. Earnings Forecast Process - The company did not conduct pre-communication with the accounting firm regarding this earnings forecast, and the specific data will be finalized in the 2025 annual report[4]. - The financial data presented is preliminary and subject to final audit results, with a commitment to timely information disclosure to investors[7]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[2].